Corporate Banner
Satellite Banner
RNAi
Scientific Community
 
Join | Sign in
Home>Resources>Webcasts>This Webcast
  Webcasts

Efficient and Specific Quantification of Mammalian microRNAs by a Novel Real-Time PCR Approach

Eric Lader, Director, QIAGEN, speaking at the RNAi World Congress 2007
Date Posted: Wednesday, December 19, 2007
Access to this article and other content is for registered users.

Join the Technology Networks Community

  • Access to the latest scientific news, products and research through Technology Networks
  • Upload and share your posters on ePosters
  • View a library of 1,800+ scientific and medical posters
  • A library of 3,000+ scientific videos on LabTube


Sign In



Forgotten your details? Click Here
If you already have an account with Technology Networks, please use your existing login details. If you do not yet have an account please join here.

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Related Content

QIAGEN Expands Leadership in Liquid Biopsies
QIAGEN and Tokai Pharmaceuticals to co-develop and commercialize the first regulated CTC-based companion diagnostic to guide treatments in prostate cancer.
Tuesday, March 17, 2015
QIAGEN, AstraZeneca to Develop Liquid Biopsy-based Companion Diagnostic
The collaboration is to advance EGFR mutation profiling in lung cancer patients.
Monday, July 28, 2014
QIAGEN Licenses Blood Cancer Biomarkers
Exclusive global license from University of Tokyo enables development of QIAGEN assays for SF3B1 mutations, including NGS gene panels, for blood cancers.
Saturday, July 26, 2014
QIAGEN, Lilly form CDx Collaboration
Companies to co-develop companion diagnostics for simultaneous analysis of DNA and RNA biomarkers in common cancers.
Friday, May 30, 2014
QIAGEN Reports Fourth Quarter and Full-Year 2013 Results
Company reports adjusted net sales OF $1.31 billion for 2013 with growth in all regions and customer classes.
Thursday, January 30, 2014
QIAGEN Expands Pipeline of Promising New Biomarkers for Development of Companion Diagnostics
Several lymphoma-related biomarkers, including EZH2 Y641 gene mutations, rights acquired from British Columbia Cancer Agency.
Monday, June 10, 2013
QIAGEN Achieves Milestone with U.S. Approval of Companion Diagnostic for Colorectal Cancer
U.S. launch of therascreen® KRAS RGQ PCR kit offers enhanced approach to guide treatments for approximately 110,000 patients annually in U.S. with colorectal cancer.
Wednesday, July 11, 2012
QIAGEN Expands Access to State-of-the-Art HPV Screening in China
Coinciding with International Women’s Day, QIAGEN also joins fifth year of campaign to provide free HPV testing to underprivileged women in China.
Thursday, March 08, 2012
QIAGEN to Acquire SABiosciences
Transaction adds to QIAGEN’s content engine for development of future diagnostics and boosts the Company’s presence in pharma discovery and validation.
Tuesday, November 10, 2009
Nobel Prize to HPV Researcher Highlights Importance of Cervical Cancer Screening and Prevention
The Nobel Prize-winning discovery of the causal link between human papillomavirus (HPV) and cervical cancer has spurred lifesaving prevention technologies – such as HPV testing and HPV vaccines - that are helping to eradicate cervical cancer globally.
Tuesday, October 07, 2008
Qiagen Forms a User Forum for High-Throughput RNAi Screening
The user forum aims to facilitate advances in RNAi screening in drug target identification and systems biology.
Tuesday, March 28, 2006
Qiagen Develops Leading Solutions for RNA Interference
Qiagen will develop world’s largest collection of validated siRNAs through an extensive validation project.
Tuesday, December 13, 2005
Qiagen Delivers the Human Druggable Genome siRNA Set
This second generation siRNA set enables gene silencing studies of 6992 potential human druggable targets.
Friday, September 30, 2005
Scientific News
Personalized Screening for Ovarian Cancer
With 60% of women diagnosed with ovarian cancer dying within five years of diagnosis there has been considerable efforts to try to detect the disease at an earlier stage.
Outsmarting HIV With Vaccine Antigens Made to Order
AIDS vaccine researchers may be one step closer to outwitting HIV, thanks to designer antibodies and antigens made to order at Duke University.
Protein Responsible for Blood Vessel Growth in Tumours Discovered
Scientists have discovered a new protein which triggers the growth of blood vessels in breast cancer tumours which have spread to the brain, a common location which breast cancer can spread to.
Potential New Class of Cancer Drugs
Scientists have found a way to stop cancer cell growth by targeting the Warburg Effect, a trait of cancer cell metabolism that scientists have been eager to exploit.
Major Step for Implantable Drug-Delivery Device
MIT spinout signs deal to commercialize microchips that release therapeutics inside the body.
Delivering Drugs to the Right Place
Thomas Weimbs has developed a targeted drug delivery method that could potentially slow the progression of polycystic kidney disease.
Study Finds Addition of Epigenetic Data Improves Predictions of Complex Traits
Researchers reported that combining genetic and epigenetic associations can bolster phenotypic predictions.
Remote-Controlled Drug Delivery
A team of researchers has created a new implantable drug-delivery system using nanowires that can be wirelessly controlled.
Stopping a Single Enzyme Could Help Treat Leukemia
EPFL scientists show how inactivating a single enzyme could effectively eradicate an aggressive form of leukemia. The principles could apply to other cancers as well.
Evo-Engineered CRISPR-Cas9s Hit More Gene-Editing Targets
Scientists have engineered a more effective CRISPR- Cas9 system paving the way for more advanced applications.
Scroll Up
Scroll Down
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters